Cancer rates rising as researchers explore ivermectin's potential

The article reports rising cancer rates, including a 1.1% annual increase in colorectal cancer deaths among people under 50 since 2005, and describes renewed interest in repurposing existing drugs such as ivermectin and mebendazole for cancer research.

The article links a recent high-profile death from colorectal cancer to wider concerns about rising cancer rates, especially among younger adults. It notes an estimated 1.1% annual increase in colorectal cancer deaths for people under 50 since 2005. The piece summarizes interest in repurposing existing antiparasitic drugs, including ivermectin and mebendazole, for cancer research. The article also reports calls for more rigorous preclinical work and well-designed clinical trials to assess these drugs' effects. Key reported facts: - The article reports the death of actor James Van Der Beek at age 48 from colorectal cancer and frames it as drawing attention to rising cancer rates. - It states that colorectal cancer deaths in people under 50 have increased by about 1.1% per year since 2005. - The article cites a systematic review and other commentary that describe laboratory and anecdotal findings on ivermectin and mebendazole and say these findings support further study. - It notes that the article mentions Anthony Letai of the National Cancer Institute acknowledged scientific interest warranting more preclinical study, and that the article describes a commercial offering of compounded ivermectin plus mebendazole. Summary: Rising cancer rates, particularly of colorectal cancer in younger adults, are highlighted as a concern and as context for renewed interest in repurposing existing drugs. The article reports calls from authors and some researchers for additional preclinical work and well-designed clinical trials, but specific trial plans or timelines are not given. Undetermined at this time